Palivizumab

A review of its use in the protection of high risk infants against respiratory syncytial virus (RSV)

Joseph M. Geskey, Neal J. Thomas, Gretchen L. Brummel

Research output: Contribution to journalReview article

14 Citations (Scopus)

Abstract

Respiratory syncytial virus (RSV) is a leading cause of hospitalization in children less than 1 year of age and causes substantial morbidity. Although there is not currently a vaccine available to prevent RSV infection, prophylaxis with the humanized monoclonal antibody palivizumab has been shown to reduce the rate of RSV hospitalization in premature infants and those infants with chronic lung disease or congenital heart disease. Because palivizumab has not been shown to have a beneficial clinical effect on established RSV disease such as reducing the rate of mechanical ventilation and mortality in children afflicted with RSV, there has been considerable debate as to the cost-benefit ratio of administering palivizumab according to international guidelines. Palivizumab has demonstrated a favorable side-effect profile in clinical trials without the development of anti-palivizumab antibodies. Future studies are needed to determine whether palivizumab, or other more potent monoclonal antibodies which are currently undergoing clinical trials, will reduce the long-term sequelae of RSV infection such as the development of wheezing and asthma.

Original languageEnglish (US)
Pages (from-to)33-43
Number of pages11
JournalBiologics: Targets and Therapy
Volume1
Issue number1
StatePublished - 2007

Fingerprint

Respiratory Syncytial Viruses
Respiratory Syncytial Virus Infections
Hospitalization
Clinical Trials
Antibodies, Monoclonal, Humanized
Child Mortality
Respiratory Sounds
Virus Diseases
Artificial Respiration
Premature Infants
Lung Diseases
Cost-Benefit Analysis
Palivizumab
Anti-Idiotypic Antibodies
Heart Diseases
Chronic Disease
Vaccines
Asthma
Monoclonal Antibodies
Guidelines

All Science Journal Classification (ASJC) codes

  • Oncology
  • Immunology and Allergy
  • Pharmacology (medical)
  • Gastroenterology
  • Rheumatology

Cite this

@article{ab76e134794645368cbea6691c71f2ab,
title = "Palivizumab: A review of its use in the protection of high risk infants against respiratory syncytial virus (RSV)",
abstract = "Respiratory syncytial virus (RSV) is a leading cause of hospitalization in children less than 1 year of age and causes substantial morbidity. Although there is not currently a vaccine available to prevent RSV infection, prophylaxis with the humanized monoclonal antibody palivizumab has been shown to reduce the rate of RSV hospitalization in premature infants and those infants with chronic lung disease or congenital heart disease. Because palivizumab has not been shown to have a beneficial clinical effect on established RSV disease such as reducing the rate of mechanical ventilation and mortality in children afflicted with RSV, there has been considerable debate as to the cost-benefit ratio of administering palivizumab according to international guidelines. Palivizumab has demonstrated a favorable side-effect profile in clinical trials without the development of anti-palivizumab antibodies. Future studies are needed to determine whether palivizumab, or other more potent monoclonal antibodies which are currently undergoing clinical trials, will reduce the long-term sequelae of RSV infection such as the development of wheezing and asthma.",
author = "Geskey, {Joseph M.} and Thomas, {Neal J.} and Brummel, {Gretchen L.}",
year = "2007",
language = "English (US)",
volume = "1",
pages = "33--43",
journal = "Biologics: Targets and Therapy",
issn = "1177-5475",
publisher = "Dove Medical Press Ltd.",
number = "1",

}

Palivizumab : A review of its use in the protection of high risk infants against respiratory syncytial virus (RSV). / Geskey, Joseph M.; Thomas, Neal J.; Brummel, Gretchen L.

In: Biologics: Targets and Therapy, Vol. 1, No. 1, 2007, p. 33-43.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Palivizumab

T2 - A review of its use in the protection of high risk infants against respiratory syncytial virus (RSV)

AU - Geskey, Joseph M.

AU - Thomas, Neal J.

AU - Brummel, Gretchen L.

PY - 2007

Y1 - 2007

N2 - Respiratory syncytial virus (RSV) is a leading cause of hospitalization in children less than 1 year of age and causes substantial morbidity. Although there is not currently a vaccine available to prevent RSV infection, prophylaxis with the humanized monoclonal antibody palivizumab has been shown to reduce the rate of RSV hospitalization in premature infants and those infants with chronic lung disease or congenital heart disease. Because palivizumab has not been shown to have a beneficial clinical effect on established RSV disease such as reducing the rate of mechanical ventilation and mortality in children afflicted with RSV, there has been considerable debate as to the cost-benefit ratio of administering palivizumab according to international guidelines. Palivizumab has demonstrated a favorable side-effect profile in clinical trials without the development of anti-palivizumab antibodies. Future studies are needed to determine whether palivizumab, or other more potent monoclonal antibodies which are currently undergoing clinical trials, will reduce the long-term sequelae of RSV infection such as the development of wheezing and asthma.

AB - Respiratory syncytial virus (RSV) is a leading cause of hospitalization in children less than 1 year of age and causes substantial morbidity. Although there is not currently a vaccine available to prevent RSV infection, prophylaxis with the humanized monoclonal antibody palivizumab has been shown to reduce the rate of RSV hospitalization in premature infants and those infants with chronic lung disease or congenital heart disease. Because palivizumab has not been shown to have a beneficial clinical effect on established RSV disease such as reducing the rate of mechanical ventilation and mortality in children afflicted with RSV, there has been considerable debate as to the cost-benefit ratio of administering palivizumab according to international guidelines. Palivizumab has demonstrated a favorable side-effect profile in clinical trials without the development of anti-palivizumab antibodies. Future studies are needed to determine whether palivizumab, or other more potent monoclonal antibodies which are currently undergoing clinical trials, will reduce the long-term sequelae of RSV infection such as the development of wheezing and asthma.

UR - http://www.scopus.com/inward/record.url?scp=70350069949&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350069949&partnerID=8YFLogxK

M3 - Review article

VL - 1

SP - 33

EP - 43

JO - Biologics: Targets and Therapy

JF - Biologics: Targets and Therapy

SN - 1177-5475

IS - 1

ER -